Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Table 5 Survival in trials comparing gemcitabine to gemcitabine plus platinum analog

Reference	Year	Treatment regimen	Median survival (mo)	p	HR	95% CI
Louvet	2005	Gemcitabine	7.1	0.13	0.82	0.64 – 1.05
		Gemcitabine (FDR) + Oxaliplatin	9.0
Poplin	2006	Gemcitabine (standard)	4.9	--	0.83*	0.69 – 1.00
		Gemcitabine (FDR)	6.0	--	0.88**	0.73 – 1.05
		Gemcitabine (FDR) + Oxaliplatin	5.9
Heinemann	2006	Gemcitabine	6.0	0.15	0.80	0.59 – 1.08
		Gemcitabine + Cisplatin	7.5
Colucci	2002	Gemcitabine	5.0	0.48	0.87	0.58 – 1.29
		Gemcitabine + Cisplatin	7.5
Viret	2004	Gemcitabine	6.7	0.73	0.92	0.59 – 1.45
		Gemcitabine + Cisplatin	8.0

ISSN: 1471-2407